Tech Company Financing Transactions
Revolution Medicines Funding Round
Revolution Medicines closed a $25 million Series A funding round on 12/22/2016. Investors included The Column Group and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
12/22/2016
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
The Column Group (Larry Lasky)
Proceeds Purpose
Proceeds from this expanded round will support the company as it continues advancing its discovery programs toward clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Saginaw Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Revolution Medicines (Nasdaq: RVMD) discovers and develops important new medicines for cancer patients by translating frontier oncology targets--proteins that drive the growth of cancers or that control immune responses that can defeat them.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Goldsmith
Chief Operating Officer
Margaret Horn
Vice President
Adrian Gill
Vice President
Richard Hansen
Vice President
Walter Reiher
Vice President
Jan Smith
Vice President
Xiaolin Wang
VP - Finance
Jack Anders
VP - Human Resources
Luan Wilfong
VP - R & D
Steve Kelsey
Browse more venture capital transactions:
Prev: 12/22/2016: QSpex Technologies venture capital transaction
Next: 12/22/2016: Veran Medical Technologies venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs